These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 8002159)
1. Diffuse intraepidermal deposition of immunoreactants on direct immunofluorescence: a clue to the early diagnosis of epidermal necrolysis. King T; Helm TN; Valenzuela R; Bergfeld WF Int J Dermatol; 1994 Sep; 33(9):634-6. PubMed ID: 8002159 [TBL] [Abstract][Full Text] [Related]
2. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523 [TBL] [Abstract][Full Text] [Related]
3. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722 [TBL] [Abstract][Full Text] [Related]
4. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC; Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739 [TBL] [Abstract][Full Text] [Related]
5. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856 [TBL] [Abstract][Full Text] [Related]
8. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Villada G; Roujeau JC; Clérici T; Bourgault I; Revuz J Arch Dermatol; 1992 Jan; 128(1):50-3. PubMed ID: 1739287 [TBL] [Abstract][Full Text] [Related]
9. Toxic epidermal necrolysis in Stevens--Johnson syndrome. Assaad D; From L; Ricciatti D; Shapero H Can Med Assoc J; 1978 Jan; 118(2):154-6. PubMed ID: 757383 [TBL] [Abstract][Full Text] [Related]
10. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Paquet P; Jennes S; Rousseau AF; Libon F; Delvenne P; Piérard GE Burns; 2014 Dec; 40(8):1707-12. PubMed ID: 24726294 [TBL] [Abstract][Full Text] [Related]
11. Ofloxacin: a probable cause of toxic epidermal necrolysis. Melde SL Ann Pharmacother; 2001 Nov; 35(11):1388-90. PubMed ID: 11724089 [TBL] [Abstract][Full Text] [Related]
12. Allopurinol-induced toxic epidermal necrolysis. Dan M; Jedwab M; Peled M; Shibolet S Int J Dermatol; 1984 Mar; 23(2):142-4. PubMed ID: 6698688 [TBL] [Abstract][Full Text] [Related]
13. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941 [TBL] [Abstract][Full Text] [Related]
14. Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses. Mizukawa Y; Shiohara T Clin Exp Dermatol; 2010 Jul; 35(5):493-7. PubMed ID: 19874369 [TBL] [Abstract][Full Text] [Related]
15. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. de Prost N; Mekontso-Dessap A; Valeyrie-Allanore L; Van Nhieu JT; Duong TA; Chosidow O; Wolkenstein P; Brun-Buisson C; Maître B Crit Care Med; 2014 Jan; 42(1):118-28. PubMed ID: 23989174 [TBL] [Abstract][Full Text] [Related]